Lee Wen-Ling, Yen Ming-Shyen, Chao Kuan-Chong, Yuan Chiou-Chung, Ng Heung-Tat, Chao Hsiang-Tai, Lee Fa-Kung, Wang Peng-Hui
Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan, ROC; Department of Nursing, Oriental Institute of Technology, New Taipei City, Taiwan, ROC; Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC.
Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
J Chin Med Assoc. 2014 May;77(5):221-6. doi: 10.1016/j.jcma.2014.02.007. Epub 2014 Mar 30.
The "gold standard" treatment for endometrial cancer is completely staged surgery, followed by radiation or chemotherapy, based on the final pathological surgical stage and requirements. In the primary treatment of endometrial cancers, hormones are rarely taken into consideration after primary surgery. Primary treatment with hormones to preserve fertility in younger women with endometrial cancer is an attractive option, and many successful cases have been reported, although the majority of them finally received definite therapy, including total hysterectomy. The role of hormone therapy is often delayed in recurrent disease; response rates to progestins and tamoxifen or aromatase inhibitors in advanced/recurrent endometrial cancers are approximately 15-20% and nearly ≤ 10%, respectively. This review is focused on updated information and recent knowledge on the use of hormones in the management of women with advanced or recurrent endometrial cancers.
